GENIP PLC

Regulatory Filings • Mar 26, 2025

National Storage Mechanism | Additional information

RNS Number : 1420C

GenIP PLC

26 March 2025

26 March 2025 

GenIP Plc

("GenIP" or the "Company")

Contract Win

GenIP Plc, a technology business providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, is pleased to announce it has secured a contract worth approximately USD$65,000 with a Singapore-based research institute (the "Client").

This contract, covering the delivery of 100 GenAI-enhanced analytical assessments, is part of a wider bid process with leading Asian institutions referred to in GenIP's announcement 13 March 2025.

The award results from GenIP's ongoing sponsorship of key technology transfer initiatives and marketing activities in leading Southeast Asian technology hubs.

Analytical assessment revenue will be recognised upon report production by GenIP and delivery to the Client.

Melissa Cruz, CEO of GenIP, commented:

"We are delighted to partner with a leading research and innovation institution in Singapore to accelerate the commercialisation of new technological discoveries. This collaboration demonstrates the broad application of our technology evaluation services by supporting cutting-edge clinical and healthcare research and innovation. Furthermore, this contract underscores the significant size of the addressable market for our technology commercialisation services."

For further information regarding GenIP, please visit www.genip.ai , or contact:

GenIP Plc Melissa Cruz, CEO		Via Redchurch Communications
Redchurch Communications (Financial PR) John Casey		genip@weareredchurch.com

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUVVWRVKUOUAR